Ruxience®
ACTIVE PRINCIPLE:
Rituximab
INDICATION:
B-cell chronic lymphocytic leukemia
Rheumatoid Arthritis
microscopic polyangiitis
Pemphigus
DATE:
01/04/2020
STATUS:
Authorized
ACTIVE PRINCIPLE:
Rituximab
INDICATION:
B-cell chronic lymphocytic leukemia
Rheumatoid Arthritis
microscopic polyangiitis
Pemphigus
DATE:
01/04/2020
STATUS:
Authorized